UNSPSC 51322501: Dextrothyroxine

This classification denotes a thyroid agent with the molecular formula C15H11I4NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4W9K63FION, chemically known as 3,5,3,5-tetraiodothyronine but generally known as dextrothyroxine, which bears US NIH Compound Identifier 853. European Medicines Agency schedules Dextrothyroxine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01651MIG. World Health Organization schedules dextrothyroxine in its Anatomical Therapeutic Chemical (ATC) Classification.

As of Q4 2014, DEXTROTHYROXINE remains the US FDA Preferred Term for this commodity. Dextrothyroxine bears US NLM identifiers UMLS ID C0011824 and NCI Concept Code C61719. SMILES: Ic1cc(CC(N)C(=O)O)cc(I)c1Oc1cc(I)c(O)c(I)c1.

UNSPSC 51322501 Dextrothyroxine is a Commodity code purchasing pharmaceutical compounds for use by state and local government health agencies, emergency response services, and cooperative purchasing alliances. The recent opportunities show state and local governments buying advanced life support medications, generic pharmaceuticals, and over-the-counter products through a mix of competitive sealed bids and cooperative agreements. The City of Tampa's Fire Rescue department, for example, solicited four specific medication line items (Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials) for emergency medical services, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) established a multi-state contract vehicle for generic multi-source pharmaceuticals and OTC products across participating state and local facilities. Issuing bodies include city purchasing departments, state health agencies, and cooperative purchasing organizations serving multiple jurisdictions. The MMCAP agreement involves three authorized national wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) and extends to Oregon; vendors must maintain relationships with at least two of the three wholesalers and comply with cGMP, DSCSA, and FDA requirements, with expiration dates of at least one year from manufacture and six-month minimum shelf life.

Recent activity spans Florida, Texas, and the multi-state Minnesota cooperative covering Oregon. The City of Tampa issued an IFB (Bid No. 26-P-00188) with a response date of April 8, 2026 and an estimated contract value of $40,000 for one-year supply with optional two-year renewals, designated as a Small Local Business Enterprise sheltered market with a 5 percent bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, signaling early-stage strategy development without immediate procurement timelines or funding commitments. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) sought generic pharmaceuticals and OTC products with awards effective July 1, 2026, using a two-year initial contract term for new responders with optional MMCAP extensions, and evaluated primarily on price competitiveness (75 percent weight) alongside compliance, EDI capability, and administrative fees; all products required on market by May 15, 2026.